We become the most trusted partner of our customers and make a better life for patients
Pipeline
KP-TR
Program Target
VEGF, TGF-beta
Disease Indication
Neovascular glaucoma
Neovascular glaucoma (NVG) a secondary glaucoma characterized by the development of neovascularization of the eye, elevated intraocular pressure, and poor visual prognosis. occurrence in patients with diabetic retinopathy, central retinal vein occlusion (CRVO), and branch retinal vein occlusion (BRVO)
KP-TR mechanism
KP-FR Novel VEGF/TGF beta blocking Fc fusion protein A new anti-neovascular glaucoma drug potential First–in-Class Product
PHONE
031-8025-6901
FAX
031-888-6699
Copyright 2021 KPBioscience. All right reserved.
Privacy | service | Contact us